Ke Liu
- Biotechnology top 0.5%
- Molecular Biology top 1%
- Advanced biosensing and bioanalysis techniques 24
- RNA Interference and Gene Delivery 17
- RNA modifications and cancer 15
- Natural product bioactivities and synthesis 13
- Cancer-related gene regulation 11
- Cancer Research top 2%
- Cancer-related molecular mechanisms research 11
- Cell Biology top 1%
- Endoplasmic Reticulum Stress and Disease 14
- Oncology top 2%
- Peptidase Inhibition and Analysis 14
- Co-authors
- David BermudesClaudia GravekampShibin ZhouTodd R. GrahamXianhong WangFosong WangFenghua FuShaowei Chen
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Ke Liu
387 papers receiving 9.9k citations
Hit Papers
Peers
Comparison fields: 5 of 187
- Biotechnology 704
- Molecular Biology 4.6k
- Cancer Research 841
- Cell Biology 790
- Oncology 1.2k
Countries citing papers authored by Ke Liu
This map shows the geographic impact of Ke Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke Liu more than expected).
Fields of papers citing papers by Ke Liu
This network shows the impact of papers produced by Ke Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke Liu. The network helps show where Ke Liu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ke Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2024 | 1 | |
| 3 | New clinical trial design in precision medicine: discovery, development and directionbreakdown → | 2024 | 74 |
| 4 | 2024 | 0 | |
| 5 | 2024 | 0 | |
| 6 | 2023 | 14 | |
| 7 | 2023 | 43 | |
| 8 | 2023 | 14 | |
| 9 | 2023 | 1 | |
| 10 | 2022 | 1 | |
| 11 | 2022 | 9 | |
| 12 | 2022 | 128 | |
| 13 | 2020 | 24 | |
| 14 | 2019 | 24 | |
| 15 | 2019 | 44 | |
| 16 | 2018 | 221 | |
| 17 | 2018 | 16 | |
| 18 | 2009 | 4 | |
| 19 | 2004 | 88 | |
| 20 | 2003 | 96 |
About Ke Liu
Ke Liu is a scholar working on Molecular Biology, Cancer Research, Oncology, Pharmacology and Aging, having authored 407 papers that have together received 10.1k indexed citations. Recurring topics across this work include Advanced biosensing and bioanalysis techniques (24 papers), RNA Interference and Gene Delivery (17 papers), RNA modifications and cancer (15 papers), Peptidase Inhibition and Analysis (14 papers), Endoplasmic Reticulum Stress and Disease (14 papers), Natural product bioactivities and synthesis (13 papers), Cancer-related gene regulation (11 papers) and Cancer-related molecular mechanisms research (11 papers). The work is most often cited by research in Biotechnology (704 citations), Molecular Biology (4.6k citations), Cancer Research (841 citations), Cell Biology (790 citations) and Oncology (1.2k citations). Ke Liu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include David Bermudes, Claudia Gravekamp, Shibin Zhou, Todd R. Graham, Xianhong Wang, Fosong Wang, Fenghua Fu, Shaowei Chen, Song Yang and Zhaolin Hua. Their work appears in journals such as Scientific Reports, Cancer Research, Nature Communications, Drug Metabolism and Disposition and Molecules.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.